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Summary To evaluate the sensitivity and specificity of immunohistochemical analysis in relation to the
standard cytological examination of the cerebrospinal fluid (CSF) in patients with either a solid tumour or a
haematological malignancy and possible leptomeningeal disease, 68 CSF-samples derived from 68 patients
were examined. The sensitivity of immunohistochemical analysis was 0.54 and its specificity 0.98. Only one
patient had a positive immunohistochemistry and a negative cytology. The gain of adding immunohistochem-
istry to cytology is nearly 8%. It is concluded that immunohistochemistry should not be used as a screening
test for leptomeningeal disease in patients with cancer.
A diagnosis of meningeal carcinomatosis (MC) or meningeal
lymphomatosis (ML) can be difficult to obtain (Wasserstrom
et al., 1982; van Zanten et al., 1988a). The mainstay of
diagnosis is the cytological examination (Glass et al., 1979)
of the cerebrospinal fluid (CSF) although in the last decade
novel methods became available, i.e. detection of tumour-
markers (van Zanten et al., 1988b) and more recently
immunohistochemical techniques (Coakham et al., 1984a,b;
Goodson & Strauss, 1979; Hancock & Medley, 1983).
Monoclonal antibodies against specific antigens can detect
(either qualitatively or, more often, quantitatively) malignant
cells. One report (Boogerd et al., 1988) is available consider-
ing the sensitivity and specificity of immunohistochemical
methods compared to standard cytological examination, but
this concerns only solid tumours. We evaluated these tech-
niques in patients with solid tumours and haematological
malignancies.
Methods
A total of 135 CSF-samples, obtained by lumbar puncture,
were available for evaluation from a total of 68 patients. The
indication for lumbar puncture in each patients was clinical
suspicion of a neurological disorder in a patient with a
diagnosis of cancer. The main neurological disorders were the
clinical diagnoses of neoplastic meningitis, radiculopathy and
spinal cord compression.
Only the first CSF-sample for each patient was evaluated
and analysed for total cell count, lactate dehydrogenase and
protein levels, cytological and immunohistochemical analysis.
Cytological analysis followed standard procedures, i.e. a
cytospin smear was made, coloured and then visually
classified. Immunohistochemical analysis (using the indirect
alkaline phosphatase technique) depended on the type of
primary tumour. For detecting carcinomas in general, use
was made of monoclonal antibodies (moAbs) CAM 5.2,
cytokeratine 8, 18, 19 and 115D8 (MAM-6AG). Whenever
specific tumour type associated moAbs were available these
were used as well. For instance moc- in case of small cell
lung cancer, parlan-U (CEA) in case of gastrointestinal tract
tumours and antiprostate specific antigens in combination
with antiprostate specific acid phosphatase in case of prostate
cancer. For detecting sarcomas and melanomas VIM-9
(vimentin) was used in combination with appropriate sar-
comatype and melanomatype associated moABs such as
antidesmin (myogenic sarcoma) anti-HMW (melanomas).
In haematological malignancies use was made of the
known phenotype of the tumour. For instance in case of a
B-cell proliferation moAbs leul4 (CD22) and the leul2
(CS19) were used in combination with anti-kappa and anti-
lambda (in case of B cell acute lymphoblastic leukaemia,
VILA-1 (CDIO) and TdT was used as well). In case of a
T-cell proliferation, leul4 (CD22) and anti-lambda and anti-
kappa were used with leul1 (CD7), DKT11 (CD2), leuDA
(CD4) and leu2 (CD8). In the case of Hodgkin's lymphoma,
BERH2 (CD30) and leuml were used to detect Hodgkin's
cells. In case of myeloid proliferation myeloid differentiation
markers were used such as TdT, leu47 (CD13), My7 (CD33),
VIMD5 (CD15) and anti-myeloperoxidase.
Results
In 68 patients the following malignancies were represented:
solid tumours: breast carcinoma 15, small cell lung cancer
two, non-small cell lung cancer three, gastrointestinal cancer
two, cancer of the urogenital tract eight, prostate three,
sarcoma one, head-and-neck cancer one, adenocarcinoma of
unknown origin one; haematological malignancies: acute
lymphoblastic leukaemia six, acute myeloid leukaemia two,
chronic myeloid leukaemia one, chronic lymphomatous
leukaemia one, multiple myeloma two, non-Hodgkin lym-
phoma 19 and Hodgkin's lymphoma one.
Since preliminary analysis did not demonstrate any
differences between haematological malignancies and solid
tumours, these tumour-groups will be considered together.
Table I shows results for all patients with regard to
cytological and immunohistochemical examination, classified
as negative or positive. Correlation between the two types of
examination was very high (X2<0.001). In only one patient,
suffering from acute lymphoblastic leukaemia, the immuno-
histochemical analysis was positive and the cytological
analysis negative. The opposite was found in six patients. All
patients with a positive cytology or immunohistochemistry
Table I Comparison between results on histochemical and
cytological analysis for the presence of pathological cells
Immlnohistochemistry
Negative Positive
Haematological Solid Haematological Solid
Cytology tumours twnours tumours tumours All
Negative 21 33 1 0 55
Positive 6 0 4 3 13
All 26 33 5 3 68
See text for details.
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had clinical signs and progression compatible with a diag-
nosis of neoplastic meningitis. Neurological signs included
cranial nerve dysfunction, mental changes or multiple
radicular deficits. Considering cytology the gold standard, the
results as shown in Table I indicate that 13 out of68 patients
suffered from neoplastic meningitis. The sensitivity of
immunohistochemistry then is 0.54 (7 positive on immuno-
histochemistry vs 13 positive on cytology) and its specificity is
0.98 (54 negative on immunohistochemistry vs 55 negative on
cytology). However, the extra yield of immunohistochemical
analysis in 68 patients is just one. Combining cytology and
immunohistochemistry the gain is nearly 8%.
Spinal fluid protein and LDH levels did not influence the
results on immunohistochemical analysis. The majority of
positive cytologies (53.8%) were observed in patients with a
cell count of less than 11 cells (Table II). Even in the
presence of a low cell count (<11 cells) immunohisto-
chemical analysis is still feasible and can lead to positive
results (37.5%).
Discussion
A diagnosis of MC or ML is usually made on clinical
grounds and can be confirmed by radiological methods (CT-
scan, myelography) and, most importantly, CSF cytology
(Olsen et al., 1974; Little et al., 1974; Glass et al., 1979).
When malignant cells, using standard cytological techniques,
are found in the CSF of a patient with a previously
undetected cancer, it is often unclear what type of malig-
nancy is present. Under these circumstances, using a broad
panel of monoclonal antibodies, immunohistochemistry has
been proven to be very helpful in determining the nature of
the tumour (Coakham et al., 1984a,b). However, when the
patient is known with cancer and cytology is negative, it is
uncertain whether immunohistochemistry is more sensitive
than cytology to detect cancer cells.
Boogerd et al. (1988) analysed this question in 118 samples
ofCSF, largely obtained by a ventricular tap via an Ommaya
Table II Results of immunohistochemical and cytological
examinations as related to cell number
Neg. Pos. Neg. Pos.
Cell count ImmJ a Imm.a Cyto.a Cyto.a Alla
1-10 85 37.5 85.5 53.8 79.4
11-25 10 25 10.9 15.3 11.8
26-50 - - - - -
51-100 - - - - -
101-1,000 5 25 3.6 23.1 7.4
> 1,000 - 12.5 - 7.7 1.5
Allb 60 8 55 13 68
aPercentages of total for each column. bTotal number for each
column.
reservoir, in patients with meningeal carcinomatosis. These
samples were drawn however from only 20 patients. Cytology
was tumour positive in 83 CSF-samples and immunohisto-
chemistry in 85. Five times cytology was positive and
immunohistochemistry negative. The opposite occurred seven
times. From their data one can calculate a sensitivity of 0.94
and a specificity of 0.80 for immunohistochemistry. Possibly
their true sensitivity and specificity are lower, since more
than one CSF-sample per patient was used. Sensitivity and
specificity for the first CSF-sample in each patient were not
stated. They conclude that adding immunohistochemistry to
the standard cytological examination is not justified as a
routine procedure, since the gain was 9%.
Our results were obtained in a larger series but confirm
their observations. Our CSF-samples showed in 90% similar
results on both cytology and immunohistochemistry. Only
one patient had positive immunohistochemistry and a
negative cytology and in this patient the cell count was high.
We conclude that immunohistochemistry should not be used
as a screening test for leptomeningeal disease in patients with
cancer. Only when CSF cytology fails in patients with a
strong suspicion of carcinomatous or lymphomatous lepto-
meningitis, may immunohistochemistry be helpful.
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